x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011699
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly235 of human AGPAT2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | AGPAT2 |
| UniProt No. | O15120 |
| Gene ID | 10555 |
| Gene Description | The 1-acylglycerol-3-phosphate-O-acyltransferase 2 enzyme catalyzes the acylation of lysophosphatidic acid into phosphatidic acid, which is a precursor for the synthesis of triacylglycerol and phospholipid. AGPAT2 is highly expressed in adipose tissues, liver, and skeletal muscle. The induced knockdown of AGPAT2 expression results in decreased expression of adipogenic proteins and delayed expression of adipogenic marker proteins, suggesting that AGPAT2 plays an important role in adipocyte growth and differentiation. Mutations in the corresponding AGPAT2 gene cause autosomal recessive congenital generalized lipodystrophy type 1, also described as Berardinelli-Seip syndrome. Patients with CGL1 are born without detectable white adipose tissue and tend to develop severe insulin resistance, hypertriglyceridemia, and type 2 diabetes during childhood. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
